<DOC>
	<DOCNO>NCT00353457</DOCNO>
	<brief_summary>This phase II study induction chemotherapy ( capecitabine , oxaliplatin cetuximab ( erbitux ) ) follow capecitabine , oxaliplatin , cetuximab radiotherapy follow surgery follow adjuvant capecitabine , oxaliplatin cetuximab locally advance resectable rectal cancer .</brief_summary>
	<brief_title>Capecitabine , Oxaliplatin &amp; Erbitux Given Throughout Multi-Modal Therapy Locally Advanced Rectal Adenocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm nonmetastatic , measurable , locally advanced ( T3 T4 ) rectal adenocarcinoma If available , tumor tissue must send investigational immunohistochemical evaluation EGFR status The distal border tumor must peritoneal reflection ( defined 12 cm anal verge proctoscopy ) Transmural penetration tumor demonstrate CT + endorectal ultrasound MRI ECOG PS 02 No prior chemotherapy , biologic therapy radiation therapy Age &gt; = 18 year old Laboratory value : ANC &gt; = 1500/mm3 ; Platelets &gt; = 100,000/mm3 ; Hgb &gt; = 9 g/dL ; Estimated CrCl &gt; 50 mL/min ; Serum bilirubin &lt; = 1.5 x ULN ; AST ALT &lt; = 3.0 x ULN ; Negative proteinuria base dip stick reading Patients must either child bear potential negative pregnancy test upon study enrollment . Patients must agree continue contraception 30 day date last study drug administration . Pregnant lactate woman . Women childbearing potential either positive pregnancy test upon study enrollment . Women/men childbearing potential use reliable appropriate contraceptive method . Patients must agree continue contraception 30 day date last study administration . Life expectancy &lt; 3 month Serious , uncontrolled , concurrent infection ( ) Concurrent use chemotherapy indicate study protocol investigational agent patient receive investigational drug &lt; 4 week prior randomization . Prior therapy specifically directly target EGFR pathway . Prior severe infusion reaction monoclonal antibody Any prior therapy Oxaliplatin Prior pelvic irradiation reason Prior unanticipated severe reaction fluoropyrimidine therapy , know sensitivity 5fluorouracil know DPD deficiency Treatment carcinoma within last five year , except cure nonmelanoma skin treat insitu cervical cancer Participation investigational drug study within 4 week precede start study treatment Major surgery within 4 week study treatment , without complete recovery Known , exist uncontrolled coagulopathy Unwillingness give write informed consent Unwillingness participate inability comply protocol duration study Known allergy hypersensitivity platinumcontaining drug Peripheral sensory neuropathy functional impairment Interstitial pneumonia extensive symptomatic interstitial fibrosis lung Pleural effusion ascites cause respiratory compromise Acute hepatitis know HIV Any follow concurrent severe and/or uncontrolled medical condition could compromise participation study : uncontrolled high blood pressure , history labile hypertension , history poor compliance antihypertensive regimen ; unstable angina pectoris ; symptomatic congestive heart failure ; myocardial infarction &lt; 6 month prior randomization ; serious uncontrolled cardiac arrhythmia ; uncontrolled diabetes ; active uncontrolled infection ; impairment gastrointestinal function GI disease may significantly alter absorption Capecitabine . Evidence CNS metastases history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant , preclude informed consent , interfere compliance oral drug intake .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Adjuvant therapy</keyword>
	<keyword>Rectal cancer</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Erbitux</keyword>
</DOC>